Spontaneous Recurrence of Methamphetamine-lnduced Paranoid-Hallucinatory States in Female Subjects: Susceptibility to Psychotic States and Implications for Relapse of Schizophrenia

In this study, we examined the relationship between increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic changes, and susceptibility to subsequent spontaneous recurrences of methamphetamine (MAP) psychosis (i.e., flashbacks). The subjects were 81 physically healthy females. Plasma monoamine metabolite levels were assayed in: 19 flashbackers, of whom 11 experienced a single flashback and 8 exhibited subsequent flashbacks; 20 non-flashbackers with a history of MAP psychosis; 8 subjects with persistent MAP psychosis; and 23 MAP users and 11 non-user controls. All 19 flashbackers had undergone frightening and stressful experiences during previous MAP use. Mild psychosocial stressors then triggered their flashbacks. During flashbacks, plasma norepinephrine levels increased, with a small increase in plasma levels of 3-methoxytyramine, which is an index of dopamine release. Among the 19 flashbackers, the 8 with subsequent episodes had increased NE levels and slightly increased 3-methoxytyramine levels, while the 11 with a single episode displayed small increases in norepinephrine and 3-methoxytyramine levels. Thus, noradrenergic hyperactivity and increased dopamine release in response to mild psychosocial stressors may be responsible for the development of flashbacks. Robust noradrenergic hyperactivity with slightly increased DA release in response to mild stress may induce susceptibility to subsequent flashbacks. Flashbacks and schizophrenia may share the pathophysiology of susceptibility to recurrence of paranoid-hallucinatory states such as stress sensitization, and also noradrenergic hyperactivity and enhanced DA release. Thus, flashbacks may provide an appropriate model of susceptibility to paranoid-hallucinatory states of schizophrenia. The model psychosis is a potential tool for validating basic neurobiological concepts thought to be related to the schizophrenia. A better understanding of the neurobiological mechanisms of susceptibility to recurrence could provide useful information in the development of strategies for preventing relapse.

References

• 1 Abercrombie E D, Jacobs B L. Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats. 1. Acutely presented stressful and nonstressful stimuli.  J Neurosci. 1987;  7 2837-2843
• 2 Andermann L F, Savard G, Meencke H J, McLachlan R, Moshé S, Andermann F. Psychosis after resection of ganglioglioma or DENT: evidence for an association.  Epilepsia. 1999;  40 83-87
• 3 Anisman H, Zacharko R M. Behavioral and neurochemical consequences associated with stressors.  Ann NY Acad Sci. 1995;  771 205-225
• 4 Asaad G, Shapiro B. Hallucinations: theoretical and clinical overview.  Am J Psychiatry. 1986;  143 1088-1097
• 5 Bell D S. Comparison of amphetamine psychosis and schizophrenia.  Br J Psychiatry. 1965;  111 701-707
• 6 Breier A, Buchanan R W, Waltrip II R W, Listwak S, Holmes C, Goldstein D S. The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy.  Neuropsychopharmacology. 1994;  10 1-7
• 7 Bremner J D, Krystal J H, Southwick S M, Charney D S. Functional neuroanatomical correlates of the effects of stress on memory.  J Traumatic Stress. 1995;  8 527-553
• 8 Brown A S, Gewirtz G, Harkavy-Friedman J, Cooper T, Brébion G, Amador X F, Malaspina D, Gorman J M. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.  Neuropsychopharmacology. 1987;  17 317-325
• 9 Castellani S, Ziegler M G, van Kammen D P, Alexander P E, Siris S G, Lake C R. Plasma norepinephrine and dopamine-β-hydroxylase activity in schizophrenia.  Arch Gen Psychiatry. 1982;  39 1145-1149
• 10 Charpusta S J, Wyatt R J, Masserano J M. Effects of single and repeated footshock on dopamine release and metabolism in the brains of fisher rats.  J Neurochem. 1997;  68 2024-2031
• 11 Dalmaz Y, Peyrin L. Relations entre la 3-méthoxytyramine urinaire et le metabolisme péripherioque de la dopamine chez l'homme et chez l'enfant.  Archiv Inter Physiol Biochim. 1978;  86 257-270
• 12 Dimsdale J E, Moss J. Plasma catecholamines in stress and exercise.  JAMA. 1980;  243 340-342
• 13 Gouzoulis-Mayfrank E, Hermle L, Thelen B, Sass H. History, rationale and potential of human experimental hallucinogenic drug research in psychiatry.  Pharmacopsychiatry. 1998;  31 (2 Suppl) 63-68
• 14 Green A I, Alam M Y, Boshes R A, Waternaux C, Pappalardo K M, Fitzgibbon M E, Tsuang M T, Schildkraut J J. Haloperidol response and plasma catecholamines and their metabolites.  Schizophr Res. 1993;  10 33-37
• 15 Havilcek L L, Crain R D. Practical statistics for physical sciences. American Chemical Society, Washington DC 1988
• 16 Heal D J, Frankland A TJ, Buckett W R. A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detention studies with drugs which alter dopamine metabolism in the brain.  Neuropharmacology. 1990;  29 1141-1150
• 17 Holroyd S H, Rabins P, Finkelstein D, Nicholson M C, Chase G A, Wisniewski S C. Visual hallucinations in patients with macular degeneration.  Am J psychiatry. 1992;  149 1701-1706
• 18 Holsten F. Flashbacks: a personal follow-up.  Arch Psychiatr Nervenkr. 1976;  222 293-304
• 19 Irwin J, Ahiluwalia P, Anisman H. Sensitization of norepinephrine activity following acute and chronic footshock.  Brain Res. 1986;  379 98-103
• 20 Javitt D C, Zukin S R. Recent advances in the phencyclidine model of schizophrenia.  Am J Psychiatry. 1991;  148 1301-1308
• 21 Kent A P, Stern G M, Webster R A. The effect of benserazide on the peripheral and central distribution and metabolism of lovodopa after acute and chronic administration in the rat.  Br J Pharmacol. 1990;  100 743-748
• 22 Landau S L. International dictionary of medicine and biology. A Wiley Medical Publication, New York, Chichester, Brisbane, Toronto, Singapore 1986 III
• 23 Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies.  Brain Res Rev. 2000;  31 371-384
• 24 Lieberman J A, Kinon B J, Loebel A D. Dopammergic mechanisms in idiopathic and drug-induced psychoses.  Schizophr Bull. 1990;  16 97-110
• 25 Lieberman J A, Sheitman B B, Kinon B J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficit and dysfunction in neuronal regulation and plasticity.  Neuropsychopharmacology. 1997;  17 205-229
• 26 Maeda S, Miyauchi J, Sakane M, Satto M, Maki S, Goto K, Matsuda M. Does endothelin-1 participate in the exercise-induced changes of blood flow distribution of muscles in humans?.  J Appl Physiol. 1997;  82 1107-1111
• 27 Matefy R E, Hayes C, Hirsh J. Psychedelic drug flashbacks, subjective reports and biographical data.  Addict Behav. 1978;  3 165-178
• 28 Millns H, Woodward M, Bolton-Smith C. Is it necessary to transform nutrient variables prior to statistical analyses?.  Am J Epidemiol. 1995;  141 251-262
• 29 Nagaoka S, Iwamoto N, Arai H. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical response to halopendol treatment.  Biol Psychiatry. 1997;  41 857-864
• 30 Nuechterlein K H, Dawson M E, Ventura J, Gitlin M, Subotnik K L, Snyder K S, Mintz J, Bartzokis G. The vulnerability/stress model of schizophrenic relapse: a longitudinal study.  Acta Psychiatr Scand. 1994;  89 58-64
• 31 Ohashi H. Prison health issues: agenda item 2, the 15^th Asian and Pacific Conference of Correctional Administrators (in Japanese).  Japanese Journal of Correction. 1996;  107 36-46
• 32 Ozawa A. Normal and abnormal values: Catecholammes. Sogonnsho (in Japanese).  [General Practice of Medicine]. 1991;  40 1332-1338
• 33 Péronnet F, Blier P, Brisson G, Diamond P, Ledoux M, Volle M. Plasma catecholammes at rest and exercise in subjects with high- and low-trait anxiety.  Psychosom Med. 1986;  48 52-58
• 34 Petty F, Chae Y -I, Kramer C, Jordan S, Wilson L. Learned helplessness sensitizes hippocampal norepinephrine to mild restress.  Biol Psychiatry. 1994;  35 903-908
• 35 Post R M. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder.  Am J Psychiatry. 1992;  149 999-1010
• 36 Risbo A, Jessen K, Hagelsten J O. Catechoiamine response to the clinical use of alpha adrenergic receptor blocking agents.  Acta Anaesthesiol Scand. 1983;  27 72-74
• 37 Robinson T E, Becker J B, Young E A, Akii H, Castaneda E. The effects of footshock stress on regional brain dopamine metabolism and pituitary (β-endorphin release in rats previously sensitized to amphetamine.  Neuropharmacology. 1987;  26 679-691
• 38 Roy A, Pickar D, Jong J D, Karoum F, Linnoila M. Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine.  Arch Gen Psychiatry. 1988;  45 849-857
• 39 Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia.  Schizophr Bull. 1992;  18 115-122
• 40 Segal D S, Janowsky D S. Psychostimulant-induced behavioral effects: possible models of schizophrenia. In: Lipton MA, DiMascio A, Killam KF: Psychopharmacology: a generation of progress. Rave Press, New York 1978: 1113-1123
• 41 Southwick S M, Krystal J H, Morgan A, Johnson D, Nagy L M, Nicolaou A, Heninger G R, Charney D S. Abnormal noradrenergic function in posttraumatic stress disorder.  Arch Gen Psychiatry. 1993;  50 266-274
• 42 Spielberger C D. Manual for the State-Trait Anxiety Inventory. Consulting Psychologist Press. Palo Alto, California 1983
• 43 Taylor D C. Mental state and temporal lobe epilepsy: a correlative account of 100 patients treated surgically.  Epilepsia. 1972;  13 727-765
• 44 Thurm I, Haefner H. Perceived vulnerability, relapse risk and coping in schizophrenia: an explorative study.  Eur Arch Psychiatr Neurol Sci. 1987;  237 46-53
• 45 Tuck J R. Effects of chlorpromazine, thioridazine and haloperidol on adrenergic transmitter mechanisms in man.  Eur J Clin Pharmacol. 1973;  6 81-87
• 46 van der Kolk B A, Fisler R. Dissociation and fragmentary nature of traumatic memories: overview and exploratory study.  J Traumatic Stress. 1995;  8 505-525
• 47 van Kammen D P. The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis.  Psychol Med. 1991;  21 881-895
• 48 van Kammen D P, Ågren H, Yao J K, O'Connor D T, Gurklis J, Peters J L. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.  Am J Psychiatry. 1994;  151 379-384
• 49 von Voigtlander P F, Burian M A, Althaus T S, Williams L R. Effects of chronic haloperidol on vitamin E levels and monoamine metabolism in rats fed normal and vitamin E deficient diets.  Res Commun Chem Pathol Pharmacol. 1990;  68 343-352
• 50 Wang M T, Yoshioka M, Imai K, Tamura Z. Gas-liquid chromatographic and mass fragmentographic determination of 3-O-methylated catecholamines in human plasma.  Clin Chim Acta. 1975;  63 21-27
• 51 Westerink B HC, Spaan S J. On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain.  J Neurochem. 1982;  38 680-686
• 52 Wood P L, Altar C A. Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons utility of 3-methoxytyramine measurements.  Pharmacol Rev. 1988;  40 163-187
• 53 Yui K, Goto K, Ikemoto S, Ishiguro T. Methamphetamine psychosis: spontaneous recurrence of paranoid-hallucinatory states and monoamine neuro transmitter function.  J Clin Psychopharmacol. 1997;  17 34-43
• 54 Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan G E, Sheitman B B, Lieberman J A, Bracha S H, Ali S F. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization.  Mol Psychiatr. 1999;  4 512-523
• 55 Yui K, Goto K, Ikemoto S, Ishiguro T. Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: noradrenergic hyperactivity with contribution from dopaminergic hyperactivity.  J Clin Psychopharmacol. 2000;  20 165-174